In Q3 of last year, we commented on the risk that Delta-⁸ THC (∆⁸THC) presented hemp operators, and the industry at large.  The immediate benefit to companies active in ∆⁸ markets was, and is, undeniable.  The collapse of hemp prices – or hemp derivatives pricing – combined with COVID to brew a perfect storm for hemp entrepreneurs.   

Current legislation for ∆⁸ is ambiguous, but it isn’t reasonable to expect the psychoactive substance to be unregulated in the open marketplace. In October of last year